JamesEUdelsonMD
Cardiology • Boston, MAAdult Congenital Heart Disease, Cardiac Electrophysiology, Heart Failure & Transplantation, Nuclear Cardiology
Professor, Medicine, Tufts Medical Center
Dr. Udelson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
750 Washington St
New England Medical CTR
Boston, MA 02111Phone+1 617-636-8066
Education & Training
Tufts Medical CenterFellowship, Cardiovascular Disease, 1987 - 1989
Newton-Wellesley HospitalResidency, Internal Medicine, 1981 - 1984
New York Medical CollegeClass of 1981
Certifications & Licensure
MA State Medical License 1983 - 2025
MD State Medical License 1986 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2010-2013
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium. Start of enrollment: 2006 Nov 01
- Heart Muscle Viability and Remodeling in Individuals Post-Heart Attack Start of enrollment: 2004 Jan 01
- Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg Start of enrollment: 2005 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1167 citationsEffects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome TrialMarvin A. Konstam, Mihai Gheorghiade, John C. Burnett, Liliana Grinfeld, Aldo P. Maggioni
JAMA. 2007-03-28 - 233 citationsHypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.Barry J. Maron, Ethan J. Rowin, Susan A. Casey, Mark S. Link, John R. Lesser
Journal of the American College of Cardiology. 2015-05-12 - 654 citationsHypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract ObstructionMartin S. Maron, Iacopo Olivotto, Andrey G. Zenovich, Mark S. Link, Natesa G. Pandian
Circulation. 2006-11-21
Journal Articles
- Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data EvolveJames E Udelson, Ethan J Rowin, JAMA Cardiology
- Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients with Heart Failure with Preserved Ejection FractionJames E Udelson, Margaret M Redfield, Marvin A Konstam, JAMA
- State-of-the-Art Paper Heart Failure with Improved Ejection Fraction: Is It Possible to Escape One’s Past?James E Udelson, Gaurav Gulati, ScienceDirect
- Join now to see all
Lectures
- It's All About Me: Individualizing Your Approach to Statin: Pharmacology Session II2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Imaging in the Management of Acute Chest PainAmerican Heart Association, Scientific Sessions 2008, New Orleans, Louisiana, USA
- Imaging in the Management of Acute Chest PainScientific Sessions 2008, New Orleans, Louisiana, USA
Other
- Imaging Coronary Anatomy and Reducing Myocardial InfarctionJames Udelson, MD, The New England Journal of Medicine
https://www.doximity.com/articles/4ae452e8-fbee-4c02-826b-ab006063d400
UpToDate, Wolters Kluwer Health - 2012-08-29 - Tolerability of the scFurosemide Infusor in Patients with Heart FailureJames Udelson, MD, Journal of Cardiac Failure
https://www.doximity.com/articles/498ad2e8-a83c-4ee1-b2b3-c7e0139a4d1e
UpToDate, Wolters Kluwer Health - 2012-06-22
Authored Content
- Imaging Coronary Anatomy and Reducing Myocardial InfarctionAugust 2018
- Tolerability of the scFurosemide Infusor in Patients with Heart FailureAugust 2018
- Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients with Heart Failure?January 2018
- Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients with Heart Failure?January 2018
- Join now to see all
Press Mentions
Heart Failure Medical Therapy Score and Clinical OutcomesSeptember 25th, 2024- Healthcare Leaders React to $1.7T Government Funding BillDecember 22nd, 2022
- VIDEO: PRECISE Trial Shows Cardiac CT with FFR-CT Significantly Improves Patient OutcomesNovember 8th, 2022
- Join now to see all
Grant Support
- Myocardial Viability And Remodeling In The OATNational Heart, Lung, And Blood Institute2004–2008
- LV Function Assessment Core LAB For Immediate TrialNational Heart, Lung, And Blood Institute2004–2006
- Foreign Cohort: Myocardial Viability And Remodeling In The Oat-NucNational Heart, Lung, And Blood Institute2005
- Domestic Cohort: Myocardial Viability And Remodeling In The Oat-NucNational Heart, Lung, And Blood Institute2005
- Selective Estrogen Receptor Modulation: Effects In Post-Menopausal WomenNational Center For Research Resources2005
- Selective Estrogen Receptor Modulation: Effects In WomenNational Center For Research Resources2004
- Estrogen Receptor Modulation--Effects In Post Menopausal WomenNational Heart, Lung, And Blood Institute2000–2004
- Estrogen Receptor Modulation--Effects In Postmenopausal Women Following MyocardiaNational Center For Research Resources2000–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
